The Role of Tumor Necrosis Factor Alpha (TNFα) in Hearing Loss and Vestibular Schwannomas

Papers of particular interest, published recently, have been highlighted as: • Of importance

1. 1.
   Mahaley MS, Mettlin C, Natarajan N, Laws ER, Peace BB. Analysis of patterns of care of brain tumor patients in the United States: a study of the brain tumor section of the AANS and the CNS and the Commission on Cancer of the ACS. Clin Neurosurg. 1990;36:347–52.PubMedGoogle Scholar
2. 2.
   Thakur JD, Banerjee AD, Khan IS, Sonig A, Shorter CD, Gardner GL, et al. An update on unilateral sporadic small vestibular schwannoma. Neurosurg Focus. 2012;33(3):E1.  https://doi.org/10.3171/2012.6.FOCUS12144.CrossRefPubMedGoogle Scholar
3. 3.
   Jacob A, Oblinger J, Bush ML, et al. Preclinical validation of AR42, a novel histone deacetylase inhibitor, as treatment for vestibular schwannomas. Laryngoscope. 2012;122:174–89.CrossRefPubMedGoogle Scholar
4. 4.
   Goutagny S, Raymond E, Esposito-Farese M, Trunet S, Mawrin C, Bernardeschi D, et al. Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas. J Neuro-Oncol. 2015;122(2):313–20.  https://doi.org/10.1007/s11060-014-1710-0.CrossRefGoogle Scholar
5. 5.
   Sugarman BJ, Aggarwal BB, Hass PE, Figari IS, Palladino MA, Shepard HM. Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro. Science. 1985;230(4728):943–5.  https://doi.org/10.1126/science.3933111.CrossRefPubMedGoogle Scholar
6. 6.
   Braumüller H, Wieder T, Brenner E, et al. T-helper-1-cell cytokines drive cancer into senescence. Nature. 2013;494:361–5.CrossRefPubMedGoogle Scholar
7. 7.
   Zhao X, Rong L, Zhao X, Rong L, Zhao X, Li X, et al. TNF signaling drives myeloid-derived suppressor cell accumulation. J Clin Invest. 2012;122(11):4094–104.  https://doi.org/10.1172/JCI64115.CrossRefPubMedPubMedCentralGoogle Scholar
8. 8.
   Elinav E, Nowarski R, Thaiss CA, Hu B, Jin C, Flavell RA. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer. 2013;13(11):759–71.  https://doi.org/10.1038/nrc3611.CrossRefPubMedGoogle Scholar
9. 9.
   Roosli C, Linthicum FH, Cureoglu S, Merchant SN. Dysfunction of the cochlea contributing to hearing loss in acoustic neuromas: an underappreciated entity. Otol Neurotol. 2012;33(3):473–80.  https://doi.org/10.1097/MAO.0b013e318248ee02.CrossRefPubMedPubMedCentralGoogle Scholar
10. 10.
    Matthies C, Samii M. Management of 1000 vestibular schwannomas (acoustic neuromas): clinical presentation. Neurosurgery. 1997;40(1):10.Google Scholar
11. 11.
    (1996) The early history of the neurofibromatoses: evolution of the concept of neurofibromatosis type 2. Arch Otolaryngol Head Neck Surg 122:1240–1249.Google Scholar
12. 12.
    Nadol JB, Diamond PF, Thornton AR. Correlation of hearing loss and radiologic dimensions of vestibular schwannomas (acoustic neuromas). Am J Otol. 1996;17(2):312–6.PubMedGoogle Scholar
13. 13.
    Caye-Thomasen P, Dethloff T, Hansen S, Stangerup S-E, Thomsen J. Hearing in patients with intracanalicular vestibular schwannomas. Audiol Neurotol. 2007;12, 12(1)Google Scholar
14. 14.
    Gouveris HT, Victor A, Mann WJ. Cochlear origin of early hearing loss in vestibular schwannoma. Laryngoscope. 2007;117:680–3.CrossRefPubMedGoogle Scholar
15. 15.
    Stankovic KM, Mrugala MM, Martuza RL, Silver M, Betensky RA, Nadol JB, et al. Genetic determinants of hearing loss associated with vestibular schwannomas. Otol Neurotol. 2009;30(5):661–7.  https://doi.org/10.1097/MAO.0b013e3181a66ece.CrossRefPubMedGoogle Scholar
16. 16.
    Lassaletta L, Martínez-Glez V, Torres-Martín M, Rey JA, Gavilán J. cDNA microarray expression profile in vestibular schwannoma: correlation with clinical and radiological features. Cancer Genet Cytogenet. 2009;194(2):125–7.  https://doi.org/10.1016/j.cancergencyto.2009.06.016.CrossRefPubMedGoogle Scholar
17. 17.
    Silverstein H. A rapid protein test for acoustic neurinoma. Arch Otolaryngol. 1972;95(3):202–4.  https://doi.org/10.1001/archotol.1972.00770080344003.CrossRefPubMedGoogle Scholar
18. 18.
    Silverstein H. Labyrinthine tap as a diagnostic test for acoustic neurinoma. Otolaryngol Clin N Am. 1973;6(1):229–44.Google Scholar
19. 19.
    Schmitt HA, Pich A, Schröder A, Scheper V, Lilli G, Reuter G, et al. Proteome analysis of human perilymph using an intraoperative sampling method. J Proteome Res. 2017;16(5):1911–23.  https://doi.org/10.1021/acs.jproteome.6b00986.CrossRefPubMedGoogle Scholar
20. 20.
    Lysaght AC, Kao S-Y, Paulo JA, Merchant SN, Steen H, Stankovic KM. Proteome of human perilymph. J Proteome Res. 2011;10(9):3845–51.  https://doi.org/10.1021/pr200346q.CrossRefPubMedPubMedCentralGoogle Scholar
21. 21.
    Ji H, Cao R, Yang Y, et al. TNFR1 mediates TNF-α-induced tumour lymphangiogenesis and metastasis by modulating VEGF-C-VEGFR3 signalling. Nat Commun. 2014;5:4944.CrossRefPubMedGoogle Scholar
22. 22.
    Brieger J, Bedavanija A, Lehr H-A, Maurer J, Mann WJ. Expression of angiogenic growth factors in acoustic neurinoma. Acta Otolaryngol. 2016;123:1040–5.CrossRefGoogle Scholar
23. 23.
    • Plotkin SR, Stemmer-Rachamimov AO, Barker FG, Halpin C, Padera TP, Tyrrell A, et al. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med. 2009;361:358–67. First demonstration that VEGF blockade can improve hearing in patients with NF2 vestibular schwannomas. CrossRefPubMedPubMedCentralGoogle Scholar
24. 24.
    Plotkin SR, Merker VL, Halpin C, Jennings D, McKenna MJ, Harris GJ, et al. Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients. Otol Neurotol. 2012;33(6):1046–52.  https://doi.org/10.1097/MAO.0b013e31825e73f5.CrossRefPubMedGoogle Scholar
25. 25.
    Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A. 1975;72(9):3666–70.  https://doi.org/10.1073/pnas.72.9.3666.CrossRefPubMedPubMedCentralGoogle Scholar
26. 26.
    Pennica D, Nedwin GE, Hayflick JS, Seeburg PH, Derynck R, Palladino MA, et al. Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature. 1984;312(5996):724–9.  https://doi.org/10.1038/312724a0.CrossRefPubMedGoogle Scholar
27. 27.
    Gray PW, Aggarwal BB, Benton CV, Bringman TS, Henzel WJ, Jarrett JA, et al. Cloning and expression of cDNA for human lymphotoxin, a lymphokine with tumour necrosis activity. Nature. 1984;312(5996):721–4.  https://doi.org/10.1038/312721a0.CrossRefPubMedGoogle Scholar
28. 28.
    Aggarwal BB, Kohr WJ, Hass PE, Moffat B, Spencer SA, Henzel WJ, et al. Human tumor necrosis factor. Production, purification, and characterization. J Biol Chem. 1985;260(4):2345–54.PubMedGoogle Scholar
29. 29.
    Probert L. TNF and its receptors in the CNS: the essential, the desirable and the deleterious effects. Neuroscience. 2015;302:2–22.  https://doi.org/10.1016/j.neuroscience.2015.06.038.CrossRefPubMedGoogle Scholar
30. 30.
    Papathanasiou S, Rickelt S, Soriano ME, Schips TG, Maier HJ, Davos CH, et al. Tumor necrosis factor-α confers cardioprotection through ectopic expression of keratins K8 and K18. Nat Med. 2015;21(9):1076–84.  https://doi.org/10.1038/nm.3925.CrossRefPubMedPubMedCentralGoogle Scholar
31. 31.
    Zhao S, Yin KW, Goodson NJ. FRI0134 association between vitamin D deficiency and markers of disease activity in axial spondyloarthritis: table 1. Ann Rheum Dis. 2014;73(Suppl 2):430.2–430.  https://doi.org/10.1136/annrheumdis-2014-eular.2134.CrossRefGoogle Scholar
32. 32.
    Zou J, Pyykko I, Sutinen P, Toppila E. Vibration induced hearing loss in guinea pig cochlea: expression of TNF-alpha and VEGF. Hear Res. 2005;202(1-2):13–20.  https://doi.org/10.1016/j.heares.2004.10.008.CrossRefPubMedGoogle Scholar
33. 33.
    Riva C, Donadieu E, Magnan J, Lavieille J-P. Age-related hearing loss in CD/1 mice is associated to ROS formation and HIF target proteins up-regulation in the cochlea. Exp Gerontol. 2007;42(4):327–36.  https://doi.org/10.1016/j.exger.2006.10.014.CrossRefPubMedGoogle Scholar
34. 34.
    Satoh H, Firestein GS, Billings PB, Harris JP, Keithley EM. Tumor necrosis factor-alpha, an initiator, and etanercept, an inhibitor of cochlear inflammation. Laryngoscope. 2002;112(9):1627–34.  https://doi.org/10.1097/00005537-200209000-00019.CrossRefPubMedGoogle Scholar
35. 35.
    Fujioka M, Kanzaki S, Okano HJ, Masuda M, Ogawa K, Okano H. Proinflammatory cytokines expression in noise-induced damaged cochlea. J Neurosci Res. 2006;83(4):575–83.  https://doi.org/10.1002/jnr.20764.CrossRefPubMedGoogle Scholar
36. 36.
    MacArthur CJ, Pillers DA, Pang J, Kempton JB, Trune DR. Altered expression of middle and inner ear cytokines in mouse otitis media. Laryngoscope. 2011;121(2):365–71.  https://doi.org/10.1002/lary.21349.CrossRefPubMedPubMedCentralGoogle Scholar
37. 37.
    Trune DR, Larrain BE, Hausman FA, Kempton JB, MacArthur CJ. Simultaneous measurement of multiple ear proteins with multiplex ELISA assays. Hear Res. 2011;275(1-2):1–7.  https://doi.org/10.1016/j.heares.2010.11.009.CrossRefPubMedGoogle Scholar
38. 38.
    Perny M, Roccio M, Grandgirard D, Solyga M, Senn P, Leib SL. The severity of infection determines the localization of damage and extent of sensorineural hearing loss in experimental pneumococcal meningitis. J Neurosci. 2016;36(29):7740–9.  https://doi.org/10.1523/JNEUROSCI.0554-16.2016.CrossRefPubMedGoogle Scholar
39. 39.
    So H, Kim H, Lee JH, et al. Cisplatin cytotoxicity of auditory cells requires secretions of proinflammatory cytokines via activation of ERK and NF-kappaB. J Assoc Res Otolaryngol. 2007;8(3):338–55.  https://doi.org/10.1007/s10162-007-0084-9.CrossRefPubMedPubMedCentralGoogle Scholar
40. 40.
    Kim HJ, Oh GS, Lee JH, Lyu AR, Ji HM, Lee SH, et al. Cisplatin ototoxicity involves cytokines and STAT6 signaling network. Cell Res. 2011;21(6):944–56.  https://doi.org/10.1038/cr.2011.27.CrossRefPubMedPubMedCentralGoogle Scholar
41. 41.
    Kaur T, Mukherjea D, Sheehan K, Jajoo S, Rybak LP, Ramkumar V. Short interfering RNA against STAT1 attenuates cisplatin-induced ototoxicity in the rat by suppressing inflammation. Cell Death Dis. 2011;2(7):e180.  https://doi.org/10.1038/cddis.2011.63.CrossRefPubMedPubMedCentralGoogle Scholar
42. 42.
    Hoang KN, Dinh CT, Bas E, Chen S, Eshraghi AA, Van De Water TR. Dexamethasone treatment of naive organ of Corti explants alters the expression pattern of apoptosis-related genes. Brain Res. 2009;1301:1–8.CrossRefPubMedGoogle Scholar
43. 43.
    Bas E, Van De Water TR, Gupta C, Dinh J, Vu L, Martinez-Soriano F, et al. Efficacy of three drugs for protecting against gentamicin-induced hair cell and hearing losses. Br J Pharmacol. 2012;166(6):1888–904.  https://doi.org/10.1111/j.1476-5381.2012.01890.x.CrossRefPubMedPubMedCentralGoogle Scholar
44. 44.
    Pasparakis M. Immune and inflammatory responses in TNF alpha-deficient mice: a critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. J Exp Med. 1996;184(4):1397–411.  https://doi.org/10.1084/jem.184.4.1397.CrossRefPubMedGoogle Scholar
45. 45.
    Erickson SL, de Sauvage FJ, Kikly K, Carver-Moore K, Pitts-Meek S, Gillett N, et al. Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice. Nature. 1994;372(6506):560–3.  https://doi.org/10.1038/372560a0.CrossRefPubMedGoogle Scholar
46. 46.
    Pfeffer K, Matsuyama T, Kündig TM, Wakeham A, Kishihara K, Shahinian A, et al. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell. 1993;73(3):457–67.  https://doi.org/10.1016/0092-8674(93)90134-C.CrossRefPubMedGoogle Scholar
47. 47.
    Rothe J, Lesslauer W, Lötscher H, Lang Y, Koebel P, Köntgen F, et al. Mice lacking the tumour necrosis factor receptor 1 are resistant to IMF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature. 1993;364(6440):798–802.  https://doi.org/10.1038/364798a0.CrossRefPubMedGoogle Scholar
48. 48.
    Yang S, Zhang LS, Gibboni R, Weiner B, Bao S. Impaired development and competitive refinement of the cortical frequency map in tumor necrosis factor-deficient mice. Cereb Cortex. 2014;24(7):1956–65.  https://doi.org/10.1093/cercor/bht053.CrossRefPubMedGoogle Scholar
49. 49.
    Oishi N, Chen J, Zheng H-W, Hill K, Schacht J, Sha S-H. Tumor necrosis factor-alpha-mutant mice exhibit high frequency hearing loss. J Assoc Res Otolaryngol. 2013;14(6):801–11.  https://doi.org/10.1007/s10162-013-0410-3.CrossRefPubMedPubMedCentralGoogle Scholar
50. 50.
    Sharaf K, Ihler F, Bertlich M, Reichel CA, Berghaus A, Canis M. Tumor necrosis factor-induced decrease of Cochlear blood flow can be reversed by etanercept or JTE-013. Otol Neurotol. 2016;37:e203–8.CrossRefPubMedGoogle Scholar
51. 51.
    Ihler F, Sharaf K, Bertlich M, Strieth S, Reichel CA, Berghaus A, et al. Etanercept prevents decrease of cochlear blood flow dose-dependently caused by tumor necrosis factor alpha. Ann Otol Rhinol Laryngol. 2013;122(7):468–73.  https://doi.org/10.1177/000348941312200711.CrossRefPubMedGoogle Scholar
52. 52.
    Arpornchayanon W, Canis M, Ihler F, Settevendemie C, Strieth S. TNF-alpha inhibition using etanercept prevents noise-induced hearing loss by improvement of cochlear blood flow in vivo. Int J Audiol. 2013;52:545–52.CrossRefPubMedGoogle Scholar
53. 53.
    Ihler F, Pelz S, Coors M, Matthias C, Canis M. Application of a TNF-alpha-inhibitor into the scala tympany after cochlear electrode insertion trauma in guinea pigs: preliminary audiologic results. Int J Audiol. 2014;53:810–6.CrossRefPubMedGoogle Scholar
54. 54.
    Lobo D, García-Berrocal JR, Trinidad A, Verdaguer JM, Ramírez-Camacho R. Review of the biological agents used for immune-mediated inner ear disease. Acta Otorrinolaringologica (English Edition). 2013;64(3):223–9.  https://doi.org/10.1016/j.otoeng.2013.06.005.CrossRefGoogle Scholar
55. 55.
    Matteson EL, Tirzaman O, Kasperbauer J, Facer GW, Beatty CW, Fabry DA, et al. Use of methotrexate for autoimmune hearing loss. Ann Otol Rhinol Laryngol. 2016;109:710–4.CrossRefGoogle Scholar
56. 56.
    McCabe BF. Autoimmune sensorineural hearing loss. Ann Otol Rhinol Laryngol. 1979;88(5):585–9.  https://doi.org/10.1177/000348947908800501.CrossRefPubMedGoogle Scholar
57. 57.
    Demirhan E, Eskut NP, Zorlu Y, Cukurova I, Tuna G, Kirkali FG. Blood levels of TNF-α, IL-10, and IL-12 in idiopathic sudden sensorineural hearing loss. Laryngoscope. 2013;123(7):1778–81.  https://doi.org/10.1002/lary.23907.CrossRefPubMedGoogle Scholar
58. 58.
    Scherer EQ, Yang J, Canis M, et al. Tumor necrosis factor-α enhances microvascular tone and reduces blood flow in the cochlea via enhanced sphingosine-1-phosphate signaling. Stroke. 2010;41:2618–24.CrossRefPubMedPubMedCentralGoogle Scholar
59. 59.
    Haubner F, Martin L, Steffens T, Strutz J, Kleinjung T. The role of soluble adhesion molecules and cytokines in sudden sensorineural hearing loss. YMHN. 2011;144:575–80.Google Scholar
60. 60.
    Derebery MJ, Rao VS, Siglock TJ, Linthicum FH, Nelson RA. Menière’s disease: an immune complex-mediated illness? Laryngoscope. 1991;101(3):225–9.  https://doi.org/10.1288/00005537-199103000-00001.CrossRefPubMedGoogle Scholar
61. 61.
    Nacci A, Dallan I, Monzani F, Dardano A, Migliorini P, Riente L, et al. Elevated antithyroid peroxidase and antinuclear autoantibody titers in Ménière’s disease patients: more than a chance association? Audiol Neurootol. 2010;15(1):1–6.  https://doi.org/10.1159/000218357.CrossRefPubMedGoogle Scholar
62. 62.
    Gazquez I, Soto-Varela A, Aran I, Santos S, Batuecas A, Trinidad G, et al. High prevalence of systemic autoimmune diseases in patients with Meniere’s disease. PLoS One. 2011;6(10):e26759.  https://doi.org/10.1371/journal.pone.0026759.CrossRefPubMedPubMedCentralGoogle Scholar
63. 63.
    • Dilwali S, Landegger LD, Soares VY, Deschler DG, Stankovic KM. Secreted factors from human vestibular schwannomas can cause Cochlear damage. Sci Rep. 2015;5:18599. First demonstration that VS secretions rich in TNFα can cause direct cochlear damage. CrossRefPubMedPubMedCentralGoogle Scholar
64. 64.
    van Wijk F, Staecker H, Keithley E, Lefebvre PP. Local perfusion of the tumor necrosis factor α blocker infliximab to the inner ear improves autoimmune neurosensory hearing loss. Audiol Neurotol. 2006;11(6):357–65.  https://doi.org/10.1159/000095897.CrossRefGoogle Scholar
65. 65.
    Derebery MJ, Fisher LM, Voelker CCJ, Calzada A. An open label study to evaluate the safety and efficacy of intratympanic golimumab therapy in patients with autoimmune inner ear disease. Otol Neurotol. 2014;35(9):1515–21.  https://doi.org/10.1097/MAO.0000000000000566.CrossRefPubMedGoogle Scholar
66. 66.
    Gazeau P, Saraux A, Devauchelle-Pensec V, Cornec D. Long-term efficacy of infliximab in autoimmune sensorineural hearing loss associated with rheumatoid arthritis. Rheumatology. 2014;53(9):1715–6.  https://doi.org/10.1093/rheumatology/keu025.CrossRefPubMedGoogle Scholar
67. 67.
    Rahman MU, Poe DS, Choi HK. Etanercept therapy for immune-mediated cochleovestibular disorders: preliminary results in a pilot study. Otol Neurotol. 2001;22(5):619–24.  https://doi.org/10.1097/00129492-200109000-00010.CrossRefPubMedGoogle Scholar
68. 68.
    Matteson EL, Choi HK, Poe DS, Wise C, Lowe VJ, Mcdonald TJ, et al. Etanercept therapy for immune-mediated cochleovestibular disorders: a multi-center, open-label, pilot study. Arthritis Rheum. 2005;53(3):337–42.  https://doi.org/10.1002/art.21179.CrossRefPubMedGoogle Scholar
69. 69.
    • Cohen S, Shoup A, Weisman MH, Harris J. Etanercept treatment for autoimmune inner ear disease: results of a pilot placebo-controlled study. Otol Neurotol. 2005;26(5):903–7 Randomized controlled trial of etanercept treatment in patients with AIED.  https://doi.org/10.1097/01.mao.0000185082.28598.87.CrossRefPubMedGoogle Scholar
70. 70.
    Taurone S, Bianchi E, Attanasio G, et al. Immunohistochemical profile of cytokines and growth factors expressed in vestibular schwannoma and in normal vestibular nerve tissue. Mol Med Rep. 2015;12:737–45.CrossRefPubMedGoogle Scholar
71. 71.
    • Ren Y, Sagers JE, Landegger LD, Bhatia SN, Stankovic KM. Tumor-penetrating delivery of siRNA against TNFα to human vestibular schwannomas. Sci Rep. 2017;7:12922. First demonstration that tumor-targeted nanotechnology and RNA interference can be leveraged synergistically to mitigate the secretion of ototoxic molecules including TNFα. CrossRefPubMedPubMedCentralGoogle Scholar
72. 72.
    Agnihotri S, Jalali S, Wilson MR, et al. The genomic landscape of schwannoma. Nat Genet. 2016;48:1339–48.CrossRefPubMedGoogle Scholar
73. 73.
    Jobin C, Morteau O, Han DS, Balfour Sartor R. Specific NF-kappaB blockade selectively inhibits tumour necrosis factor-alpha-induced COX-2 but not constitutive COX-1 gene expression in HT-29 cells. Immunology. 1998;95(4):537–43.  https://doi.org/10.1046/j.1365-2567.1998.00646.x.CrossRefPubMedPubMedCentralGoogle Scholar
74. 74.
    Feng L, Xia Y, Garcia GE, Hwang D, Wilson CB. Involvement of reactive oxygen intermediates in cyclooxygenase-2 expression induced by interleukin-1, tumor necrosis factor-alpha, and lipopolysaccharide. J Clin Investig. 1995;95:1669–75.CrossRefPubMedPubMedCentralGoogle Scholar
75. 75.
    Dilwali S, Briët MC, Kao S-Y, Fujita T, Landegger LD, Platt MP, et al. Preclinical validation of anti-nuclear factor-kappa B therapy to inhibit human vestibular schwannoma growth. Mol Oncol. 2015;9(7):1359–70.  https://doi.org/10.1016/j.molonc.2015.03.009.CrossRefPubMedPubMedCentralGoogle Scholar
76. 76.
    Dilwali S, Kao S-Y, Fujita T, Landegger LD, Stankovic KM. Nonsteroidal anti-inflammatory medications are cytostatic against human vestibular schwannomas. Transl Res. 2015;166(1):1–11.  https://doi.org/10.1016/j.trsl.2014.12.007.CrossRefPubMedPubMedCentralGoogle Scholar
77. 77.
    Kandathil CK, Dilwali S, Wu C-C, Ibrahimov M, McKenna MJ, Lee H, et al. Aspirin intake correlates with halted growth of sporadic vestibular schwannoma in vivo. Otol Neurotol. 2014;35(2):353–7.  https://doi.org/10.1097/MAO.0000000000000189.CrossRefPubMedGoogle Scholar
78. 78.
    Stankovic KM (2017) Study of aspirin in patients with vestibular schwannoma. In: https://clinicaltrials.gov/ct2/show/NCT03079999?term=stankovic&rank=1. ClinigalTrials.gov Identifier: NCT03079999. Accessed 30 Nov 2017.
79. 79.
    Hellgren K, Smedby KE, Feltelius N, Baecklund E, Askling J. Do rheumatoid arthritis and lymphoma share risk factors?: a comparison of lymphoma and cancer risks before and after diagnosis of rheumatoid arthritis. Arthritis Rheum. 2010;62(5):1252–8.  https://doi.org/10.1002/art.27402.CrossRefPubMedGoogle Scholar
80. 80.
    Hellgren K, Smedby KE, Backlin C, Sundstrom C, Feltelius N, Eriksson JK, et al. Ankylosing spondylitis, psoriatic arthritis, and risk of malignant lymphoma: a cohort study based on nationwide prospectively recorded data from Sweden. Arthritis Rheumatol. 2014;66(5):1282–90.  https://doi.org/10.1002/art.38339.CrossRefPubMedGoogle Scholar
81. 81.
    Baecklund E, Iliadou A, Askling J, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006;54:692–701.CrossRefPubMedGoogle Scholar
82. 82.
    Burmester GR, Panaccione R, Gordon KB, McIlraith MJ, Lacerda APM. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn’s disease. Ann Rheum Dis. 2013;72(4):517–24.  https://doi.org/10.1136/annrheumdis-2011-201244.CrossRefPubMedGoogle Scholar
83. 83.
    Wolfe F, Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum. 2007;56(5):1433–9.  https://doi.org/10.1002/art.22579.CrossRefPubMedGoogle Scholar
84. 84.
    Ramiro S, Sepriano A, Chatzidionysiou K, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2017;76:1101–36.CrossRefPubMedGoogle Scholar